38 results
6-K
EX-99.1
IPHA
Innate Pharma
14 May 24
Innate Pharma Reports First Quarter 2024 Business Update And Financial Results
6:07am
of IPH6501 in Patients With Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma
oPreclinical assessment of IPH6501, a first-in-class IL2v-armed
424B5
IPHA
Innate Pharma
6 Feb 24
Prospectus supplement for primary offering
5:00pm
from the auditor attestation requirement of Section 404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, in the assessment … , as amended, or the Sarbanes-Oxley Act, in the assessment of our internal controls over financial reporting; and
to the extent that we no longer qualify
F-3
IPHA
Innate Pharma
20 Dec 23
Shelf registration (foreign)
4:45pm
, as amended, or the Sarbanes-Oxley Act, in the assessment of our internal controls over financial reporting; and
to the extent that we no longer qualify
6-K
EX-99.1
oi971df0n5tq 9o
22 Sep 23
Innate Pharma S.a. 6-K
6:00am
6-K
EX-99.1
5pytlhkw7eyylk7aml58
16 Jun 23
Innate Pharma S.a. 6-K
6:00am
424B5
f3ddr
26 Apr 23
Prospectus supplement for primary offering
4:01pm
20-F/A
60t14b 36b5g
20 Apr 23
Annual report (foreign) (amended)
8:47am
6-K
EX-99.1
cq6nnn4b0pmh7g2zja
12 Dec 22
Innate Pharma S.a. 6-K
6:00am
424B5
0r7ipb
3 May 22
Prospectus supplement for primary offering
4:36pm
F-3
3vpu0cvk
13 Jan 21
Shelf registration (foreign)
1:59pm
6-K
EX-99.1
vqopmvmf5
13 Nov 20
Innate Pharma Receives Prime Designation From the European Medicines Agency for Lacutamab in Sézary Syndrome
6:30am
6-K
EX-99.2
vkxod
8 Sep 20
Innate Pharma Reports First Half 2020 Financial Results and Business Update
6:10am
6-K
EX-99.1
n3qut4uk6o8
24 Jun 20
Current report (foreign)
6:30am
20-F
iwsndslz
24 Apr 20
Annual report (foreign)
10:43am
6-K
EX-99.1
8sszr zoigo
14 Jan 20
French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides
6:30am